glycyrrhizin on HCC in HCV

　　To elucidate the influence of a glycyrrhizin therapy on hepatocarcinogenesis rate in interferon （IFN）- resistant hepatitis C， we retrospectively analyzed 1249 patients with chronic hepatitis with or without cirrhosis. Among 346 patients with high alanine transaminase value （twice or more of upper limit of normal）， 244 patients received intravenous glycyrrhizin injection and 102 patients did not， after judgment of IFN resistance. Crude carcinogenesis rates in the treated and untreated group were 13.3%， 26.0% at the 5th year， and 21.5% and 35.5% at the 10th year， respectively （P = .0210）. Proportional hazard analysis using time-dependent covariates disclosed that glycyrrhizin treatment significantly decreased the hepatocarcinogenesis rate （hazard ratio 0.49， 95% confidence interval 0.27–0.86， P = .014） after adjusting the background features with significant covariates. Glycyrrhizin injection therapy significantly decreased the incidence of hepatocellular carcinoma in patients with IFNresistant active chronic hepatitis C， whose average aminotransferase value was twice or more of upper limit of normal after interferon.